TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01653782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Description: Guided training twice a week for six weeks. Self instructing cd for home practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self care advice
Description: Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book
Study: NCT00550056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Six session of Narrative Exposure Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Counselling
Description: Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
Study: NCT02538861

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT Imaging Test at Baptist hospital
Description: Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital
Description: The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
Study: NCT00799162

Intervention type: OTHER
Intervention: Psychophysical testing, questionnaires, and genetics
Description: pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
Study: NCT03073798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: 500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mcg of placebo is used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mcg of placebo is used
Study: NCT03119077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1161116
Description: Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Redosing of BAY1161116/placebo at dose group 1 together with itraconazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
Study: NCT01874535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg
Description: Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg
Description: Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Study: NCT02353936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily
Study: NCT02827045

Intervention type: DEVICE
Intervention: Vestibular test

Intervention type: DEVICE
Intervention: Vestibular test
Study: NCT04568174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPSGG
Description: an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
Study: NCT02538861

Intervention type: DIAGNOSTIC_TEST
Intervention: SPECT Imaging Test at West Kendall Baptist Hospital
Description: Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
Study: NCT04240353

Intervention type: OTHER
Intervention: COPD digital support service
Description: Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
Study: NCT00245882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: Care coordination with monthly follow-up by a diabetes nurse educator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Telemedicine
Description: Active care management by a nurse practitioner using home telemedicine
Study: NCT04568174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
Study: NCT00793104

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of allograft CR Plug in primary injury site
Description: Core defect and implant allograft CR plug
Study: NCT03890276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HMS EL&C training module
Description: No additional information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMS EL&C training module
Description: No additional information
Study: NCT03517319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% 1.2 ml
Study: NCT03890276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos used to supplement live trainer
Description: \[Cherrie to add\]
Study: NCT03517319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U
Study: NCT02012972

Intervention type: BEHAVIORAL
Intervention: Referral for NCD care
Description: Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
Study: NCT03517319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U
Study: NCT00599586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study: NCT03517319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
Study: NCT00045162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: 60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
Study: NCT02032316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent
Description: Renal stent placed after uncomplicated uteroscopy
Study: NCT00471094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study: NCT01186458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
Study: NCT03476226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Dysfunction Coping Strategy Teaching Sheet
Description: Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
Study: NCT01991548

Intervention type: DEVICE
Group type: OTHER
Intervention: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Study: NCT01202435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: 82.5 mg controlled release tablet administered once daily for four days.

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 25 mg
Description: 25 mg immediate release capsules administered three times daily for four days
Study: NCT02452463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study: NCT00599586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study: NCT00846612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: 1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: 1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
Study: NCT03176212

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk fat globule membrane

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk fat globule membrane
Study: NCT01984112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locked plate
Description: Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramedullary locked nail
Description: Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
Study: NCT05537428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Intervention
Description: A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
Study: NCT02202603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: single oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous standard injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous standard injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo
Study: NCT01859429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
Study: NCT04589494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride
Description: tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride
Description: tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
Study: NCT02680301

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone CREAM
Description: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone CREAM
Description: Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone OINTMENT
Description: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% triamcinolone OINTMENT
Description: Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
Study: NCT03953560

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dyspnea grade ≥ II according NYHA-WHO
Description: Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis
Study: NCT03881163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
Study: NCT00923091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine + hydroclororthiazide
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + amlodipine
Description: One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
Study: NCT02492711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: 15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: 15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
Study: NCT01850602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Study: NCT03838783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: 50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
Study: NCT02184351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxanes's clotrimazole troches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycelex® troches
Study: NCT03477929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate
Description: multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Study: NCT02452463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00796562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patient will receive Cy by IV once a day for 2 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Patients will receive TBI once a day for 4 days.
Study: NCT02355730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
Study: NCT01409499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: palliative hepatectomy followed by sorafenib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter hepatic arterial chemoembolization
Description: TACE followed by sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib monotherapy, 400mg Bid, continuously